Keratitis Xerophthalmic – Complete Medical Guide

Overview

Keratitis xerophthalmic (also called “xerophthalmic keratitis” or “dry‑eye keratitis”) is an inflammatory condition of the cornea that occurs when the ocular surface becomes excessively dry. The lack of adequate tear film leads to disruption of the corneal epithelium, allowing inflammation and, in severe cases, ulceration.

The disorder most often affects adults over the age of 40, but it can occur at any age, especially in individuals with chronic dry‑eye disease, autoimmune disorders, or a history of ocular surgery.

Estimates vary because xerophthalmic keratitis is usually grouped under the broader umbrella of “dry‑eye disease.” The Tear Film & Ocular Surface Society (TFOS) reports that dry‑eye disease affects roughly 5‑30 % of the adult population worldwide, with the more severe forms (including keratitis) representing about 2‑5 % of those cases ^[1].

Symptoms

Symptoms develop gradually and may fluctuate with environmental conditions (wind, low humidity, prolonged screen time). Common signs include:

• Foreign‑body sensation – a gritty or sandy feeling on the eye surface.
• Burning or stinging pain – often worse in dry environments or after reading.
• Redness – diffuse conjunctival injection, especially at the limbus.
• Blurred or fluctuating vision – typically improves with blinking.
• Photophobia – heightened sensitivity to light.
• Excessive tearing (reflex tearing) – paradoxical response as the eye tries to compensate for dryness.
• Eye fatigue – especially after prolonged visual tasks.
• Reduced tear production – measurable with clinical tests.
• Corneal epithelial defects – visible as small, superficial erosions on slit‑lamp examination.
• Hypersensitivity to contact lenses – intolerance or increased discomfort.

In advanced cases, patients may notice a “white spot” or ulcer on the cornea, accompanied by severe pain and vision loss.

Causes and Risk Factors

Keratitis xerophthalmic is not caused by a single factor; rather, it results from a combination of tear‑film insufficiency and inflammatory pathways.

Primary Causes

• Aqueous‑deficient dry eye – Reduced production of the watery component of tears, often due to:
  • Autoimmune diseases (e.g., Sjögren’s syndrome, rheumatoid arthritis)
  • Damage to lacrimal glands from radiation or surgery
• Evaporative dry eye – Excess tear evaporation caused by meibomian gland dysfunction, blepharitis, or exposure (e.g., facial nerve palsy).
• Environmental factors – Low humidity, high wind, air‑conditioned or heated rooms, and prolonged screen use that reduces blink rate.
• Medications – Antihistamines, isotretinoin, antidepressants, and some glaucoma drops can diminish tear production.
• Ocular surface trauma – Prior refractive surgery, laser procedures, or corneal abrasions that disrupt the epithelial barrier.

Risk Factors

• Age > 40 years
• Female gender (higher prevalence of autoimmune dry‑eye disease)
• History of autoimmune disease (Sjögren’s, lupus, RA)
• Contact lens wear, especially extended‑wear lenses
• Systemic medications that reduce tear secretion
• Previous ocular surgery (LASIK, cataract extraction)
• Exposure to smoke, dust, or chemicals

Diagnosis

Diagnosis is clinical, relying on patient history, symptom questionnaires, and objective tests to confirm tear‑film deficiency and corneal involvement.

History & Physical Examination

• Detailed symptom chronology (onset, aggravating/relieving factors)
• Review of systemic diseases and medications
• Visual acuity assessment and external eye inspection

Diagnostic Tests

1. Schirmer I Test – Filter paper strips placed in the lower fornix for 5 minutes; ≤ 5 mm wetting suggests severe aqueous deficiency ^[2].
2. Tear Break‑Up Time (TBUT) – Fluorescein dye is applied; the interval between a blink and first dry spot is measured. TBUT < 10 seconds indicates tear instability.
3. Ocular Surface Staining – Fluorescein or lissamine green highlights epithelial defects; a pattern of punctate staining is typical.
4. Meibomian Gland Evaluation – Expressibility and quality of meibum are graded to determine evaporative contribution.
5. Corneal Topography or OCT – In severe cases, imaging assesses epithelial thickness and stromal involvement.
6. Inflammatory Biomarker Tests (research use) – Tear cytokine levels (e.g., IL‑1, MMP‑9) may be elevated in active disease.

Treatment Options

Management aims to restore a stable tear film, suppress inflammation, and protect the corneal epithelium.

1. Lubrication & Tear Conservation

• Artificial tears – Preservative‑free drops (e.g., Refresh Optive, Systane Ultra) used 4–6 times daily.
• Ocular lubricating ointments – Applied at bedtime for prolonged surface coating.
• Punctal plugs – Silicone or collagen plugs inserted into puncta to retain tears; effective in up to 60 % of patients ^[3].

2. Anti‑Inflammatory Therapy

• Corticosteroid eye drops (e.g., prednisolone acetate 1 %) – Short‑term use (1–2 weeks) for acute inflammation.
• Cycloplegic/Immunomodulatory drops – Cyclosporine A 0.05 % (Restasis) or lifitegrast 5 % (Xiidra) improve tear production by reducing ocular surface inflammation.
• Oral tetracyclines (doxycycline 40 mg daily) – Decrease matrix‑metalloproteinase activity and help with meibomian gland dysfunction.

3. Meibomian Gland & Lid Hygiene

• Warm compresses (5–10 minutes, 2–3 times/day) to melt clogged meibum.
• Lip‑rub cleaning or commercial lid‑scrub wipes.
• In-office LipiFlow or intense pulsed light (IPL) therapy for refractory cases.

4. Protective Measures

• Moisture chamber goggles – Reduce evaporation in windy or low‑humidity environments.
• Humidifiers – Maintain indoor humidity at 40–50 %.
• Frequent blinking exercises, especially during screen work.

5. Surgical / Procedural Options (for severe or unresponsive cases)

• Autologous serum eye drops – Contain growth factors and vitamins; used 4–6 times daily.
• Amniotic membrane transplantation – Provides a biological bandage for persistent epithelial defects.
• Conjunctival flap or tarsorrhaphy – Mechanical protection of the cornea when other measures fail.

6. Lifestyle & Adjunctive Strategies

• Limit caffeine and alcohol (both can reduce tear production).
• Stay hydrated – aim for 2–3 L of water per day.
• Take regular breaks using the 20‑20‑20 rule (every 20 min, look at something 20 ft away for 20 seconds).

Living with Keratitis Xerophthalmic

Long‑term management focuses on symptom control, preventing recurrences, and maintaining visual acuity.

Daily Routine

1. Morning: Apply preservative‑free artificial tears; perform lid hygiene if you have blepharitis.
2. Throughout the day: Re‑apply drops as needed (usually every 2–3 hours when outdoors or in air‑conditioned rooms). Use a humidifier at work.
3. Evening: Apply lubricating ointment before sleep; consider a punctal plug check if symptoms worsen.

Monitoring Tools

• Keep a symptom diary – note triggers, drop usage, and visual changes.
• Periodic slit‑lamp examinations every 6–12 months, or sooner if symptoms flare.
• Use mobile apps validated for dry‑eye questionnaires (e.g., OSDI – Ocular Surface Disease Index) to track severity.

Work & Social Considerations

• Position computer screens slightly below eye level to promote complete blinking.
• Wear wrap‑around glasses with anti‑fog coating to reduce wind exposure.
• Inform employers about the need for regular breaks and access to eye‑lubricating products.

Prevention

Because many risk factors are modifiable, preventive steps can lower the likelihood of developing xerophthalmic keratitis.

• Control systemic disease – Work with rheumatologists or endocrinologists to keep autoimmune conditions in remission.
• Medication review – Discuss alternatives with your prescribing physician if you take drugs known to dry the eyes.
• Maintain eyelid hygiene – Daily warm compresses and gentle cleaning prevent meibomian blockage.
• Protect against environmental stressors – Use sunglasses on windy days, humidifiers indoors, and avoid direct airflow from fans or AC vents.
• Healthy diet – Omega‑3 fatty acids (fish oil, flaxseed) have been shown to improve tear film quality ^[4].
• Regular eye examinations – Early detection of tear‑film abnormalities allows prompt treatment before corneal involvement.

Complications

If untreated or poorly controlled, xerophthalmic keratitis can lead to serious ocular pathology:

• Corneal ulceration – Full‑thickness breaks in the epithelium increase infection risk.
• Infectious keratitis – Bacterial, fungal, or viral superinfection; may require intensive antimicrobial therapy.
• Scarring and neovascularization – Permanent visual impairment due to stromal opacity.
• Reduced visual acuity – Persistent irregularities in the corneal surface cause chronic blur.
• Secondary glaucoma – Chronic inflammation can affect intra‑ocular pressure.
• Photophobia and chronic pain – Significantly lowers quality of life.

When to Seek Emergency Care

---

Sources:

1. Tear Film & Ocular Surface Society (TFOS) Dry Eye Workshop II, 2017.
2. Mayo Clinic. “Schirmer tear test.” Accessed 2024.
3. American Academy of Ophthalmology. “Punctal Plugs for Dry Eye.” 2023.
4. Clinical Ophthalmology. “Omega‑3 fatty acids in dry eye disease: A systematic review.” 2022.